DANAHER CORP /DE/ News
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
see moreDANAHER CORP /DE/ Market News
5d
Danaher Corporation's Strategic Moves Bolster Position in Life Sciences and Diagnostics
- Danaher Corporation's recent acquisition of Masimo Corporation and financial performance highlight its strategic growth in the life sciences and diagnostics sectors.
10d
Danaher Corporation Completes Acquisition of Masimo Corporation
Danaher finalizes Masimo acquisition, enhancing diagnostics portfolio.
25 May at 04:30
Danaher Q1 Beat Bioprocessing Orders Ignite Upside
Danaher’s Q1 results and guidance raise confidence in a nascent bioprocessing upcycle. Strong orders, biotech sales growth and the nearing Masimo acquisition are tangible catalysts that offset diagnostic headwinds and strengthen DHR’s near-term earnings trajectory.
11 May at 04:30
Danaher Moves: Share Plan, Dividend, Sector Deals!
Danaher shareholders approved a 20M-share incentive plan and a $0.40 quarterly dividend amid mixed institutional flows and a new 52-week low. Heavy M&A in diagnostics—Chiesi–KalVista, Angelini–Catalyst, Roche–PathAI—frames sector pressure and opportunity for DHR.
04 May at 04:30
Danaher Bioprocessing Surge, Diagnostics Fall 2026
Danaher's Q1 2026 beat on EPS and showed a sharp rebound in bioprocessing orders (+30% YoY) even as Diagnostics lagged. Strong cash flow and a raised full‑year EPS guide underpin M&A plans (including the pending Masimo deal), while near‑term Diagnostics softness has pressured DHR's stock.
27 Apr at 04:30
Danaher Q1 Beat, Bioprocessing Surge, Masimo Deal
Danaher delivered a Q1 earnings beat driven by a bioprocessing rebound, raised full-year guidance, and reaffirmed its $9.9B Masimo acquisition. Diagnostics weakness and a recent stock dip temper near-term sentiment, but equipment order strength points to potential upside.
20 Apr at 04:30
Danaher (DHR) Faces Biotech Slowdown, Liquidity
Danaher (DHR) is navigating near-term pressure in its life sciences businesses as consumables and order momentum soften while the company secures liquidity to support integration of Masimo. Recent analyst target trims, a new $5B revolving credit facility, and continued strategic focus on diagnostics suggest a cautious but resilient outlook ahead of upcoming earnings.